trending Market Intelligence /marketintelligence/en/news-insights/trending/qyTFHk6kGpRfMS9K8DAU_Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Eisai cancer drug shows non-inferiority in phase 3 trial

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Eisai cancer drug shows non-inferiority in phase 3 trial

Eisai Co. Ltd.'s lenvatinib met its primary endpoint in a phase 3 trial comparing the drug as a first-line treatment against Bayer AG and Onyx Pharmaceuticals' sorafenib in patients with unresectable hepatocellular carcinoma, the most common type of liver cancer.

The drug was demonstrated to be just as effective as sorafenib with meaningful improvements in progression-free survival and objective response rate.

The result will support Eisai's regulatory submissions in U.S., Japan, China and Europe this year.